Karin von Wachenfeldt, PhD, CEO

Karin has a strong scientific expertise in Pharmaceutical development of large and small molecules. She obtained her Ph. D from Dept. of Immunotechnology at Lund University. Karin has over 20 years experience from the pharmaceutical industry (BioInvent, Ixsys Inc. PharmaciaUpjohn, Active Biotech and AstraZeneca) developing drugs for cancer and Respiratory/Inflammation. At AstraZeneca R&D Lund Karin was instrumental in the implementation of translational science and biomarker strategies within the discovery projects, and worked closely with the early clinical organization. She has complemented her scientific training and experience with a degree in marketing and leadership. Since 2011 she is the CEO and co-founder of Truly Translational Sweden AB and holds the same position in Truly Labs AB since 2015.